Saluda Medical has raised $40 million in a round led by a GlaxoSmithKline VC fund. The series D gives Saluda the means to take its spinal cord stimulation (SCS) device through a pivotal trial in the U.S. while commercializing it in Europe and its home country, Australia.
{iframe}http://www.fiercebiotech.com/medtech/gsk-fund-leads-40m-investment-saluda-setting-it-up-to-bring-bioelectronic-medicine-to{/iframe}